We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
WHX Labs Dubai 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Virus Linked to Breast Cancer Suggests a Vaccine

By Biotechdaily staff writers
Posted on 08 Jun 2004
A study has found evidence of a link between adult exposure to cytomegalovirus (CMV) and breast cancer in women under the age of 40, which suggests that a vaccine against the virus in childhood might be a way to decrease the risk of breast cancer.

The study involved 377 women, whose blood samples were tested for antibody levels to CMV and the Epstein-Barr virus. Researchers found that the women with breast cancer had higher CMV antibody levels than women without cancer. However, no link was found between the Epstein-Barr virus and breast cancer.

"The higher antibody levels could be the result of more recent infection with cytomegalovirus,” said principal researcher Dr. Ann Richardson. "This may mean that late infection with cytomegalovirus, rather than in childhood, is a risk factor for breast cancer.” It is not unusual to find links between viruses and increased cancer risk, noted Dr. Richardson. Several cancers, including cervical, liver, and some forms of leukemia are known to be caused by viruses. CMV is a common virus that is shed in breast milk as well as in saliva, urine, cervical secretions, and semen.

"Countries where most people are exposed to cytomegalovirus and other viruses in childhood have lower rates of breast cancer,” remarked Dr. Richardson. Further research is needed. If late infection with CMV is found to increase the risk of breast cancer, it might be possible to decrease the risk by exposing people to the virus by immunization in childhood.

The study was conducted by researchers at the University of Otago's Christchurch School of Medicine and Health Sciences and Dunedin School of Medicine (Dunedin, New Zealand), with colleagues from the University of Melbourne (Australia).



Related Links:
U.Otago's Christchurch School of Med.

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Gold Member
Hematology Analyzer
Medonic M32B

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
08 Jun 2004  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
08 Jun 2004  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
08 Jun 2004  |   BioResearch